As of November this year, based on Qiagen's most recent financial report, the company's trailing twelve months EPS is $1.7. During 2024, QGEN reported a per-share earnings of $0.38, which shows a decline compared to the EPS of $1.5 recorded in 2023. Qiagen's EPS for the quarterly period ending on Jun 30, 2025 came in at $0.44.
The yearly earnings per share during 2024 was $0.38, a decline of 74.7% compared to $1.5 recorded in 2023. Over the quarter ending Jun 30, 2025, the earnings per share came in at $0.44, reflecting a 153% increase compared to the same quarter a year earlier. As of June 2025, the TTM EPS is $1.7. During 2023, the annual earnings per share was $1.5, representing a decrease of 19.4% compared to 2022.
Qiagen has recorded a growth in earnings per share of 153% in the past 12 months (YoY, quarterly). During the past three years, QGEN registered an average yearly EPS growth of -44.7%. Over the last decade, QGEN had an average annual earnings per share growth of -3.1%.
| Stock name | Price to Earnings | EPS grwoth 1Y | EPS grwoth 3Y | EPS grwoth 5Y |
|---|---|---|---|---|
| QGEN Qiagen NV | 25.91 | -74.7% | -44.7% | N/A |
| HOLX Hologic Inc | 30.55 | 81.1% | -22.8% | N/A |
| BDX Becton Dickinson & Co | 32.07 | 18.3% | -5.3% | 8% |
| TMO Thermo Fisher Scientific Inc | 32.74 | 6.8% | -5.5% | 12.4% |
| GE General Electric Co | 40.36 | -28.4% | N/A | N/A |
| TECH BIO-TECHNE Corp | 127.53 | -56.1% | -35.2% | -20.7% |
All data is based on quarterly TTM periods, unless otherwise specified.